CLOs on the Move

Xperiome

www.xperiome.com

 
Xperiome is a global healthtech company that helps pharma get to know rare disease patients and their conditions faster by delivering deep insights into the patient experience. We have created Raremark as the place for the lived experience of rare disease. Raremark supports every stage of a patient`s health odyssey: a community to crowdsource wisdom, a library to catalog the lived experience, and a matching engine to find research opportunities. This data-driven knowledge bank of the rare experience allows us to match research-ready members to clinical and real-world studies, faster and smarter than ever before.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NeuroFlow

There is a health crisis in America. In every community, 1 in 4 people live with mental health disorders and the demand for behavioral health services has been amplified in the wake of COVID-19. Social isolation, economic downturns, and tense conditions have amplified the effects of depression, anxiety, and substance use disorder.

Back Nursery

Back Nursery is a Hastings, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Banyan Hypnosis Ctr-Training

Banyan Hypnosis Ctr-Training is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Canton Medical Foundation

North Canton Medical Foundation was founded in 1972 by a group of physicians who envisioned a non-profit physician group practice as a unique mechanism to bring high quality medical care to the community. Since 1972, North Canton Medical Foundation has

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.